🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Tirz made me a completely different person holy cow — looking for input

Tirz made me a completely different person holy cow — looking for input

roxy_nash Wed, Sep 10, 2025 at 7:43 PM 35 replies 1,765 viewsPage 1 of 7
This thread is more than 9 months old. Information may be outdated. Consider searching for more recent discussions.
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
Sep 10, 2025 at 7:43 PM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five. That matters when you are deciding whether a dose step has finished expressing itself.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

What I am trying to establish is how much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
34 12josh_phd_bmore, roxy_nash, tony_orlando and 31 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Sep 10, 2025 at 7:48 PM#2
roxy_nash said:
Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five.

That is correct as far as it goes, and here is where it stops going. SURMOUNT-1 landed around 20.9% mean weight loss at 15mg over 72 weeks, against roughly 15% for semaglutide 2.4mg in STEP 1. Different trials, different populations, so the comparison is indicative rather than decisive — but SURPASS-2 was a genuine head-to-head and it pointed the same way.

35 13anna.melb_AU, mark_tokyo, hans_munich and 32 others
Reply Quote Save Share Report
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Sep 10, 2025 at 7:53 PM#3
roxy_nash said:
Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five.

I read this differently from roxy_nash, on substance rather than tone. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.

36 14COA_Karl, MikeFit_NJ, InsuranceTom and 33 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Sep 10, 2025 at 7:58 PM#4

This one has a reasonably settled answer, so here it is. The GIP arm is doing real work rather than padding the label. GIP receptor agonism appears to improve adipose insulin sensitivity and lipid handling, and — counter-intuitively — GIP signalling in the CNS reduces nausea rather than adding to it, which is why tolerability at high total agonism is better than the GLP-1-only comparison would predict. SURPASS-2 is the cleanest head-to-head: tirzepatide beat semaglutide 1mg at every dose tier.

Last edited: Sep 11, 2025 at 12:58 AM
37 15pete_nash, hank_denver, carlos_SATX and 34 others
Reply Quote Save Share Report
chris_chi24
Member
389
1,678
Sep 2024
Chicago, IL
Sep 10, 2025 at 8:24 PM#5
Dr.RaviCardio said:
SURMOUNT-1 landed around 20.9% mean weight loss at 15mg over 72 weeks, against roughly 15% for semaglutide 2.4mg in STEP 1.

Adding a me-too, because a thread of one person's experience is not much use.

Last edited: Sep 10, 2025 at 11:24 PM
38 16SleepFixSam, PurityPaulOR, MaxMetOK and 35 others
Reply Quote Save Share Report
1237

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register